Skip to main content
Voyageur Pharmaceuticals Ltd. logo

Voyageur Pharmaceuticals Ltd. — Investor Relations & Filings

Ticker · VM ISIN · CA92918C1014 TSXV Manufacturing
Filings indexed 501 across all filing types
Latest filing 2020-01-10 Regulatory Filings
Country CA Canada
Listing TSXV VM

About Voyageur Pharmaceuticals Ltd.

https://voyageurpharmaceuticals.ca/

Voyageur Pharmaceuticals Ltd. develops and supplies contrast media products for medical imaging, including CT scans and fluoroscopy. The company operates using a vertically integrated "Earth to Bottle" strategy, controlling the entire supply chain from raw mineral acquisition to finished pharmaceutical product. Voyageur owns a significant, high-purity barium sulfate resource, positioning it as a secure and sustainable supplier of pharmaceutical-grade barium sulfate, the active ingredient in its commercialized contrast agents (e.g., SmoothX® and SmoothHD® series). This vertical control aims to ensure supply security and cost competitiveness, primarily targeting the North American market. The company is also actively developing iodine-based contrast media and V-Gas® Effervescent Granules to expand its portfolio of diagnostic imaging solutions.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing the submission of a pharmaceutical product registration to Health Canada by Voyageur Pharmaceuticals Ltd. It discusses product development, joint ventures, and forward-looking statements about future plans and registrations. There are no financial statements, earnings data, regulatory certifications, or voting results. The content is primarily an update on product registration and company activities, typical of a Capital/Financing Update or general corporate announcement. However, since it focuses on product registration submission and development plans rather than financing or capital structure changes, it best fits the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-01-10 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings
2020-01-10 English
Report of exempt distribution excluding schedule 1 of Form 5.pdf
Regulatory Filings
2020-01-03 English
Other securityholders documents - English.PDF
Regulatory Filings Classification · 95% confidence The document is a short certificate of amendment indicating a company name change under the Business Corporations Act. It is a regulatory announcement about a corporate change, not a financial report or detailed filing. The document length is very short (202 characters), and it does not contain financial data or detailed report content. Therefore, it fits best under Regulatory Filings (RNS) as a general compliance announcement.
2020-01-02 English
News release - English.pdf
Regulatory Filings
2019-12-31 English
News release - English.pdf
Regulatory Filings
2019-12-24 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.